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Abstract
Small molecules and antisense oligonucleotides that inhibit the translation initiation factors 
eIF4A1 and eIF4E have been explored as broad-based therapeutic agents for cancer treatment, 
based on the frequent upregulation of these two subunits of the eIF4F cap-binding complex in 
many cancer cells. Here we provide support for these therapeutic approaches with mechanistic 
studies of eIF4F-driven tumor progression in a preclinical model of melanoma. Silencing eIF4A1 
or eIF4E decreases melanoma proliferation and invasion. There were common effects on the level 
of cell cycle proteins which could explain the antiproliferative effects in vitro. Using clinical 
specimens, we correlate the common cell cycle targets of eIF4A1 and eIF4E with patient survival. 
Finally, comparative proteomic and transcriptomic analyses reveal extensive mechanistic 
divergence in response to eIF4A1 or eIF4E silencing. Current models indicate that eIF4A1 and 
eIF4E function together through the 5′UTR to increase translation of oncogenes. In contrast, our 
data demonstrate that the common effects of eIF4A1 and eIF4E on translation are mediated by the 
coding region and 3′UTR. Moreover, their divergent effects occur through the 5′UTR. Overall, 
our work shows that it will be important to evaluate subunit-specific inhibitors of eIF4F in 
different disease contexts to fully understand their anticancer actions.
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INTRODUCTION
Steady state translation initiation is primarily regulated through the cytoplasmic mRNA cap 
binding complex, eukaryotic initiation factor 4F (eIF4F), comprised of the cap binding 
protein eIF4E, the RNA helicase eIF4A and the scaffolding protein eIF4G (reviewed in (1)). 
Increased protein levels of eIF4E (2), phospho-eIF4E (3), eIF4A1 (4) and eIF4G (5) are 
associated with poor clinical outcomes in multiple cancer contexts and are linked to 
aggressive phenotypes in cellular and preclinical models (6–8). In melanoma, many of the 
known oncogenic signaling pathways converge on eIF4F (9). Targeted therapies that 
deactivate these pathways are initially effective, but nearly universal acquired resistance 
leads to high mortality rates (10). Thus, second-line inhibition of eIF4F could significantly 
extend the period of response to targeted therapies for melanoma patients.
Classic models dictate that eIF4E is the rate-limiting factor for translation initiation in most 
normal tissues (11). Under physiological conditions, mRNAs are thought to compete for 
limiting amounts of eIF4E. In this model, mRNAs with longer and more structured 5′UTRs 
are weakly translated. In cancer cells, increased availability of eIF4E leads to selective 
translation of highly-sensitive oncogenes, such as MYC (12) and VEGF (13). More recently, 
this model was extended to incorporate 5′UTR sequence elements that confer eIF4E 
sensitivity such as the terminal oligonucleotide tract (5′TOP), pyrimidine-rich translational 
element (PRTE) and cytosine-enriched regulator of translation (CERT) (14–16). However, 
5′UTR features do not explain the full spectrum of eIF4E targets (17), including the class of 
mRNAs for which eIF4E negatively regulates translation. Improved models are necessary to 
predict outcomes of therapeutic inhibition of eIF4F in cancer.
Targets of eIF4A and eIF4E have been identified using polysomal RNA association or 
ribosome profiling to estimate translation efficiency (16,18–21). Some mRNAs have 
different requirements for individual eIF4F subunits (19,22), but global effects of eIF4A1 
and eIF4E depletion have not been assessed in parallel in the same cancer model. Here, we 
characterize the phenotypic and global proteomic effects of eIF4A1 and eIF4E inhibition in 
melanoma. We show that eIF4A1 and eIF4E promote melanoma proliferation through 
shared, network-level regulation of the cell cycle, and moreover, that eIF4F-dependent cell 
cycle proteins are significant combinatorial predictors of patient survival. Finally, we 
demonstrate that intrinsic features of mRNA coding sequence (CDS) and 3′UTR, but not 
5′UTR, predict shared targets of eIF4A1 and eIF4E. These data demonstrate that eIF4A1 
and eIF4E have distinct molecular consequences in the same cancer model, which implies 
that targeting eIF4F with different subunit-specific inhibitors will influence on-target and 
off-target therapeutic outcomes.
MATERIALS AND METHODS
Additional methods are provided in supplementary file S1.
Cell culture
WM858, WM46 and A375 were cultured in high glucose DMEM (Cellgro) supplemented 
with 10% fetal bovine serum (Life Technologies). WM46 was transduced with lentivirus 
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containing empty SparQ IRES RFP vector (QM531A-2, System Biosciences), or vector 
containing eIF4A1 (4096621, Open Biosystems) or eIF4E cDNA (5295521, Open 
Biosystems). RFP positive cells in the middle quantiles were selected by flow cytometry. 
The A375 melanoma cell line was a gift from Dr. David Fisher, and WM46 and WM858 
were a gift from Dr. Levi Garraway, all obtained prior to 2012. All cell lines were 
authenticated via short tandem repeat profiling at the American Tissue Culture Repository 
on May 19, 2016.
Transient knockdown
A375 and WM858 cells were transfected with Allstars Negative Control siRNA (Qiagen) or 
gene-specific siRNA at 7.5 nM using RNAiMAX (Life Technologies). Gene-specific siRNA 
sequences were 5′-GCATGGAGATATCTCCATGCAT and 5′-
GCATGGAGATATGGACCAATT for eIF4A1 (custom design, Qiagen) and 5′-
AAGAGCGGCTCCACCACTAAA and 5′-CAAAGCTTTGCTACAAATTTA for eIF4E 
(Hs_EIF4E_1 and Hs_EIF4E_8, Qiagen). siRNA-like off-target effects were assessed by 
siRNA-check (http://projects.insilico.us/SpliceCenter/siRNACheck). miRNA-like off-target 
effects were assessed by scanning 3′UTRs for perfect matches to the 8-mer seed region of 
each oligonucleotide (underlined above).
Proliferation assays
2500 cells per well were seeded into 96-well plates and, where appropriate, transfected with 
siRNA. After 24 hours (h), cell culture medium was replaced with 10μl Wst-1 (Pierce) in 
100μl complete medium. Cells were incubated in growth conditions for 30 minutes, and 
absorbance was measured at 450 nm on a Victor 3V plate reader (Perkin Elmer). Additional 
readings were taken at 48, 72 and 96h. Blank readings were subtracted from test readings 
and net absorbance values were plotted relative to the 24h time point. Significance was 
calculated by two-way ANOVA with Dunnett’s multiple correction test (GraphPad Prism 
v7.0).
Invasion assays
4.0 × 104 (knockdown) or 2.0 × 104 (overexpression) cells were washed and resuspended in 
serum free medium. Cells were seeded in rehydrated control or Matrigel invasion chambers 
(BD Biocoat), chambers were placed in wells of a 24-well plate containing 750μl DMEM 
supplemented with 30% FBS, and plates were incubated under growth conditions for 20h. 
Non-migratory cells were removed by scrubbing twice with a cotton swab. Filters were 
washed in cold PBS, fixed in cold 100% methanol and mounted with Vectashield Hard Set 
Mounting Medium with DAPI (Vector Labs). Eight visual fields were photographed for cell 
counting. Invasion assays were performed 48h post-transfection and 4 hours post-treatment 
with 1uM rotenone, when applicable. Significance was calculated by one-way ANOVA with 
Dunnett’s multiple correction test (GraphPad Prism v7.0).
Quantitative mass spectrometry
Knockdowns were performed in triplicate in 10cm dishes and cells were collected 72h post-
transfection. Samples were processed and analyzed for MS3 mass spectrometry as 
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previously described (23). Briefly, cells were lysed, proteins were digested using LysC and 
trypsin, and peptides were labeled with Tandem Mass Tag 10-plex reagents and fractionated. 
Data were collected on an Orbitrap Fusion mass spectrometer operating in MS3 mode using 
synchronous precursor selection for MS2 to MS3 fragmentation, and forward and reverse 
sequences were searched against a Uniprot human database (February 2014) using the 
SEQUEST algorithm. Additional processing steps included protein assembly and 
quantification from peptides, and calculation of Benjamini-Hochberg false discovery rates 
(FDR). Protein levels were normalized to the percent signal in each sample relative to the 
total signal across all multiplexed samples. Differentially expressed proteins had a fold 
change ≥|1.25| in all three biological replicates and FDR <0.1 in primary and secondary 
siRNA treatments.
Pathway and network analysis
Gene set enrichment analysis was performed using GSEA (http://software.broadinstitute.org/
gsea/index.jspGene). Differentially expressed proteins for each treatment were ranked based 
on their average fold-change across triplicates and analyzed against Reactome pathways 
(http://www.reactome.org/pathways) using the GSEA Preranked tool. We applied a classic 
enrichment statistic, filtered gene sets with >500 or <15 hits, and applied an FDR threshold 
≤0.1. To visualize enrichment of common pathways, we ranked all genes based on their 
average fold-change across all knockdown treatments and performed GSEA Preranked as 
above. The normalized enrichment score calculates the degree to which a gene set is 
overrepresented at the extremes of a ranked list, accounting for size of the gene set. To 
predict functional outcomes of differentially expressed genes, we used the Diseases and 
Functions tool in Ingenuity Pathway Analysis (IPA; Qiagen). Differentially expressed cell 
cycle proteins were assigned to cell cycle phases based on their membership in Reactome 
daughter categories under the cell cycle parent category.
Cell cycle analysis
Knockdowns were performed in 6 well dishes. Cells were collected 72 hours post-
transfection, washed once in PBS, fixed in 70% ethanol for 30 min at 4°C pelleted pelleted 
at 850xg for 10 min, and washed again in PBS. Pellets were resuspended in 50ul 100ug/ml 
RNase A and incubated at room temperature for 15 min. 200ul 50ug/ml propidium iodide 
was added and the suspension was incubated in the dark at room temperature for 20 min. 
Cells were passed through a cell strainer filter and analyzed on a BD LSR II FACS machine. 
Proportions of G1, S and G2 cells were assessed in FlowJo v10. Significance was calculated 
by two-way ANOVA with Dunnett’s multiple correction test (GraphPad Prism v7.0).
Apoptosis assays
Knockdowns were performed in 6 well dishes. Cells were collected 48 or 72 hours post-
transfection, stained with the Pacific Blue Annexin V Apoptosis Detection Kit (Biolegend) 
and analyzed on a BD LSR II FACS machine. Proportions of ANXAV- and propidium 
iodide-positive cells were assessed in FlowJo v10. Significance was calculated by two-way 
ANOVA with Dunnett’s multiple correction test (GraphPad Prism v7.0).
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Patient survival
Clinical and protein expression data (level 3; normalized expression) were obtained for skin 
cutaneous melanoma patients in TCGA. All protein data were generated by the Reverse 
Phase Protein Array Core Facility at MD Anderson Cancer Center (Houston, TX), providing 
adequate internal control among samples. Significance of Kaplan-Meier survival curves was 
calculated using the Gehan-Breslow-Wilcoxon test, which does not assume equivalent 
proportional hazards over time (GraphPad Prism software v7.0).
RNA sequencing (RNA-seq)
Knockdowns were performed in duplicate in 10cm dishes. RNA was extracted 72 hours 
post-transfection using Trizol reagent. cDNA libraries were prepared from 1ug total RNA 
using the Illumina TruSeq RNA sample preparation kit, v2. Raw counts were obtained using 
the Python package ‘HTSeq-count’, and normalized using the R package ‘deseq’. 
Differentially expressed mRNAs had a fold change ≥|1.25| and FDR≤0.1.
Effect size calculation
Cliff’s D was calculated using the cliff.delta function in the R package ‘effsize’. This test 
nonparametrically measures how often the values in one distribution are larger than those in 
another distribution. Significance was calculated by the Mann-Whitney-U test using the 
wilcox.test function in R.
miRNA reporter assays
Knockdowns were performed in triplicate in 96 well plates. 24h post-knockdown, cells were 
re-transfected with 100ng psiCheck2–6X-CXCR4 and 15nM si-Scr or artificial CXCR4 
siRNA (5′-GUUUUCACUCCAGCUAACACA-3) using Lipofectamine 2000 (Life 
Technologies). Dual luciferase assays (Promega) were performed and analyzed on a Victor 
3V plate reader (Perkin Elmer) 48h after reporter transfection. miRNA-targeted Renilla 
luciferase (R-luc) was normalized to untargeted firefly luciferase (F-luc) in each well. Fold 
repression was calculated as the R-luc:F-luc ratio in the absence of CXCR4 divided by the 
R-luc:F-luc ratio in the presence of CXCR4.
RESULTS
eIF4A1 and eIF4E positively regulate melanoma proliferation and invasion
We assessed the phenotypic effects of altered eIF4F expression in melanoma short-term 
cultures (MSTC), which are expanded directly from patient biopsies and provide an accurate 
representation of melanoma in vivo (24). The highly proliferative and invasive WM858 
culture has an average doubling time of 34 hours and invasion rate of 19.5% (Fig. 1A, si-
Scr). The weakly proliferative and invasive WM46 culture has an average doubling time of 
62 hours and invasion rate of 6% (Fig. 1B, oe-Empty). Knockdown of eIF4A1 or eIF4E in 
WM858 decreased proliferation and invasion (Fig. 1A, S1A) while overexpression in WM46 
increased invasion and modestly (p=0.127) increased proliferation (Fig. 1B, S1B). These 
data show that eIF4E and eIF4A1 positively regulate melanoma proliferation and invasion, 
two critical processes underlying disease progression.
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eIF4A1 and eIF4E have disparate effects on the melanoma proteome
MSTCs accurately reflect melanoma biology, but they are not ideal for integrative molecular 
profiling because of their slow growth rates, limited proliferative capacity and variable 
transfectability. A375 is an immortalized, transfectable melanoma cell line that is even more 
invasive and proliferative than WM858 in vitro. We confirmed that knockdown of either 
eIF4A1 or eIF4E using primary and secondary siRNAs (Fig. S1C,D) reduced proliferation 
and invasion of A375 cells (Fig. 1C). Thus, A375 is a suitable model system in which to 
examine responses to eIF4F inhibition.
All previous global studies on the effects of eIF4A1 and eIF4E have relied on polysome or 
ribosome profiling, but technical biases have contributed to discordant results (22). 
Moreover, these methods do not directly assess protein levels which are more closely related 
to cellular phenotypes than mRNA levels or ribosome occupancy. To define the eIF4F-
dependent melanoma proteome, we performed triple-stage mass spectrometry (MS3) on 
A375 cells depleted of eIF4A1 or eIF4E for 72 hours. We identified 1286 and 756 
differentially expressed proteins in eIF4A1- or eIF4E-depleted melanomas, respectively 
(Fig. 2A, Table S1). eIF4A1 and eIF4E protein levels were 3.6-fold (+/−0.23, 
FDR=4.65×10−4) and 3.3-fold (+/−0.16, FDR=1.82×10−3) reduced in their respective 
treatments, and neither was affected by depletion of the other.
Among all proteins that were affected by eIF4F depletion (either eIF4A1 or eIF4E), only 
19% (320/1706) were commonly affected by depletion of both factors (Fig. 2B). This was 
surprising given the shared phenotypic outcomes in eIF4A1- or eIF4E-depleted melanomas 
and their known physical interaction as members of the eIF4F cap-binding complex. To 
independently validate this result, we performed western blotting of several differentially 
expressed proteins (Fig. S2). As additional confirmation, we computationally predicted 
siRNA-like or miRNA-like off-target effects of each siRNA. There were no alternative 
binding sites in the human transcriptome that would lead to siRNA-like off target effects, 
even when allowing up to 2 mismatches. However, there were 38 decreased proteins whose 
mRNAs contained 8-mer miRNA seed matches to the siRNAs in their 3′UTRs. Since the 
siRNAs could act like miRNAs to repress translation of these proteins, we removed these 
genes from subsequent analyses. Overall, the vast majority of factor-specific effects were 
likely due to on-target depletion of eIF4A1 and eIF4E.
eIF4A1 and eIF4E promote melanoma proliferation via shared regulation of the cell cycle 
protein network
Despite the prevalence of factor-specific changes, we hypothesized that eIF4A1 and eIF4E 
depletion elicit common phenotypes via commonly dysregulated proteins. Consistent with 
this hypothesis, the 320 common protein changes predicted decreased proliferation 
(p=1.32×10−3, activation z-score=−2.557) and tumor progression (p=3.82×10−4, activation 
z-score=−0.728). To investigate this hypothesis further, we performed Gene Set Enrichment 
Analysis among differentially expressed proteins (Fig. 2C, Table S2). Three Reactome 
pathways were commonly enriched following depletion of either factor: Cell Cycle and 
related DNA Replication were decreased while the Tricarboxylic Acid Cycle and 
Respiratory Electron Transport Chain (TCA/ETC) was increased (Fig. 2C,D).
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Core regulators of all cell cycle phases contributed to the Cell Cycle pathway enrichment 
(Fig. 3A), suggesting a general dampening of the pathway rather than checkpoint-specific 
arrest. Consistent with this, the relative proportion of cells in G0/G1, S or G2/M phase was 
not affected by eIF4A1 or eIF4E depletion (Fig. 3B). Reduced cell number in the absence of 
cell cycle phase skewing could also be due to apoptosis, but we found no evidence for 
increased apoptosis at 48 or 72 hours post-knockdown (Fig. S3, 3C), nor did we detect an 
enrichment of apoptosis pathways (Fig. 2C). Thus, we conclude that eIF4A1 and eIF4E are 
required to maintain the overall rate of entry and progression through the cell cycle in 
melanoma.
We examined the importance of eIF4F-dependent cell cycle regulation to patient outcomes 
in 328 cutaneous melanoma patients in The Cancer Genome Atlas (TCGA) for which 
reverse phase protein array data was available. We first confirmed that low expression of 
eIF4E (eIF4A1 was not queried on the array) conferred a survival advantage in this dataset 
(p=0.0149, Fig 3E), as has been reported elsewhere (25,26). We next identified three core 
cell cycle proteins queried on the array that were commonly regulated by eIF4A1 and eIF4E: 
CCND1, CDK1 and CCNB1 (Fig 3D). Low expression of each factor alone confers a small 
survival advantage that is not statistically significant (Fig. S4), but low expression of all 
three factors together conferred a strong advantage (p=0.0030, Fig. 3E). These data suggest 
that network-level upregulation of cell cycle proteins by eIF4A1 and eIF4E reduces 
melanoma patient survival.
eIF4A1 and eIF4E promote melanoma invasion via distinct mechanisms
A common mechanism underlying eIF4A1- and eIF4E-dependent invasion was less clear 
from the functional enrichment data. However, increased glycolysis is associated with 
melanoma invasion (27), which led us to hypothesize that increased expression of the 
alternative metabolic pathway, TCA/ETC, in eIF4A1- and eIF4E- depleted melanomas (Fig. 
2D) results in a metabolic switch that reduces invasion. If true, inhibiting the ETC in the 
context of eIF4A1 or eIF4E depletion should restore high levels of invasion in A375. We 
treated cells with the ETC complex I inhibitor, rotenone, in combination with si-Scr, si-
eIF4A1 or si-eIF4E. Contrary to our hypothesis, rotenone decreased invasion in the si-Scr 
treatment and had no effect on invasion in eIF4A1- or eIF4E-depleted cells (Fig. S5). Thus, 
eIF4A1 and eIF4E do not promote melanoma invasion through increased use of the 
TCA/ETC metabolic pathway. In fact, this pathway appears to promote invasion through an 
eIF4F-independent mechanism.
Because the eIF4E- and eIF4A-dependent proteomes did not reveal any common pathways 
of melanoma invasion, we examined whether eIF4A1 and eIF4E might reduce invasion 
through different mechanisms. Separate analyses of the proteomes predicted reduced 
invasion of tumor cell lines (p=2.84×10−12 and 7.42×10−4, z=−2.39 and −1.308, for eIF4A1 
and eIF4E, respectively), but the specific proteins contributing to each factor’s enrichment 
differed. Notable examples included decreased expression of alpha and beta integrins in 
eIF4A1-depleted melanomas and decreased expression of epidermal growth factor receptor 
in eIF4E-depleted melanomas (28,29). Thus, it is likely that eIF4A1 and eIF4E commonly 
regulate the invasion phenotype by different molecular mechanisms.
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Direct and indirect regulation by eIF4A1 and eIF4E shape the melanoma proteome
Proteomics links eIF4A1- and eIF4E-dependent phenotypes to changes in protein output, but 
it does not discern whether the regulatory mechanism is direct (translational) or indirect 
(transcriptional or post-transcriptional). Previous studies used translational profiling at very 
early time points to identify direct targets and mitigate effects on transcription and mRNA 
stability (18–21). We devised an alternate strategy that enriches for direct targets at later 
time points by calculating discordance between mRNA and protein fold-changes.
92% of proteins detected by MS3 were also detected at the mRNA level by RNA-seq (Fig. 
4A). Among the overlapping set, 2602 mRNAs were differentially expressed using the |
1.25|-fold threshold applied to the MS3 dataset (Table S3, Fig. S6A). We note that this 
threshold is more permissive for the RNA-seq dataset because the dynamic range of fold-
changes was 2.6-times greater than that of MS3. Despite the large number of differentially 
expressed mRNAs, the Cell Cycle and TCA/ETC pathway enrichments were diminished at 
the mRNA level (Fig. S6B, Table S2). Thus, mRNA expression changes are less indicative 
of altered cellular processes than protein expression changes in the context of eIF4A1 and 
eIF4E depletion.
We next used mRNA fold-changes to infer direct and indirect protein targets of eIF4A1 and 
eIF4E among differentially expressed proteins. Proteins were classified as direct targets if 
there was no change or an opposing change in the cognate mRNA level. This method 
identified known direct targets (Table S4), along with many novel direct targets of both 
factors. In total, 76.8% (911/1186) of eIF4A1-responsive proteins and 67.5% (468/693) of 
eIF4E-responsive proteins were direct targets (Fig. 4B). Surprisingly, nearly half of all direct 
targets were negatively regulated by eIF4A1 or eIF4E (Fig. 4B, red points), suggesting a 
prominent role for eIF4A1 and eIF4E in translational repression which has been observed 
previously, but is poorly understood (16,18–21).
To investigate the relative contributions of direct and indirect regulation on the cellular 
processes regulated by eIF4F, we focused on commonly enriched cell cycle and TCA/ETC 
pathways, which are subject to opposing regulation; the cell cycle pathway was positively 
regulated by eIF4E and eIF4A whereas the TCA/ETC pathway was negatively regulated by 
eIF4E and eIF4A; (Fig. 2D). Among 56 positively-regulated cell cycle pathway members, 
77% and 62% of proteins were direct targets of eIF4A1 and eIF4E, respectively (Fig. 4C). 
Among 23 negatively-regulated TCA/ETC pathway members, 85% and 60% of proteins 
were direct targets of eIF4A1 and eIF4E, respectively (Fig. 4C). Thus, eIF4A1 and eIF4E 
directly regulate the cell cycle by promoting translation of one set of mRNAs and directly 
regulate the TCA/ETC pathway by inhibiting translation of a different set of mRNAs.
5′UTR features predict selective effects of eIF4A1 and eIF4E on translation
To define mRNA-based determinants of positive and negative translational regulation by 
eIF4A1 and eIF4E, we calculated the effect size for intrinsic mRNA features (Fig. 5A). All 
significant features for direct targets had diminished or even opposing effects among indirect 
targets (Fig. S7), highlighting their relevance to direct translational regulation. Surprisingly, 
all significant features in the 5′UTR were specific to either eIF4A1 or eIF4E. eIF4A1 
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promotes translation of mRNAs with long, GC-rich, structured 5′UTRs which is consistent 
with its biochemical activity as an RNA helicase. In contrast, eIF4E promotes translation of 
mRNAs with shorter, less structured 5′UTRs that are depleted of upstream start codons and 
upstream open reading frames.
The negative correlation between 5′UTR structure and eIF4E levels contradicts earlier 
models (1). We examined whether the presence of eIF4E-responsive 5′UTR sequence 
elements could explain this discrepancy. TOP and PRTE elements (14,15) were present in 
less than 10% of eIF4E-dependent 5′UTRs, suggesting that they do not broadly contribute 
to eIF4E-dependent regulation in melanoma. The CERT element was previously identified 
by polysome profiling in a mouse model of eIF4E-driven oncogenic transformation (16). In 
our dataset, the CERT element was present in 47.9% of eIF4E-responsive 5′UTRs. Notably, 
the CERT element was not more prevalent among positively versus negatively regulated 
5′UTRs (Fig. S8A). However, the CERT element was present at a higher density in the 
5′UTRs and 3′UTRs of positively-regulated mRNAs containing the motif compared to 
negatively-regulated mRNAs containing the motif (p=1.87×10−2 and 5.11×10−3, 
respectively; Fig. S8B). Our data independently corroborate a role for the 5′UTR CERT 
element in eIF4E-dependent regulation and further suggest that CERT elements may play a 
similar role in the 3′UTR.
Another reason that our eIF4E-responsive 5′UTRs deviate from earlier models may be that 
compensatory mRNA changes mask protein-level changes in the context of long-term eIF4E 
depletion. For example, eIF4E is known to promote translation of many ribosomal subunit 
proteins via 5′ UTR TOP motifs (14,15), but ribosomal subunit proteins were not 
downregulated in eIF4E-depleted melanoma. To investigate whether eIF4A1 or eIF4E 
knockdown leads to compensatory increases in mRNA levels that could mask reduction in 
protein levels, we examined our mRNA expression data and found dramatic upregulation of 
ribosomal subunits at the mRNA level (Fig. S9). This finding suggests that an increased 
number of transcripts compensates for the translational defect on ribosomal subunit mRNAs. 
Despite potential confounding factors, it appears that 5′UTR composition is the primary 
differentiator between eIF4A1-regulated and eIF4E-regulated transcripts.
CDS and 3′UTR features predict common translational targets of eIF4A1 and eIF4E
CDS and 3′UTR features defined common regulation by both factors. Rare codon 
frequency, 3′UTR length, miRNA binding site density and exon junction density were the 
only significant features among the shared direct targets of eIF4A1 and eIF4E (Fig. 5A). The 
increased density of miRNA binding sites among negatively regulated transcripts was 
intriguing since previous studies have implicated both eIF4E (30) and eIF4A (31) in 
miRNA-mediated repression. To validate this observation in a controlled setting, we tested 
miRNA function in A375 cells depleted of eIF4A1 or eIF4E using a dual luciferase reporter 
assay. Depletion of either factor reduced miRNA-mediated repression (Fig. 5C). In concert 
with our genome-wide analysis of shared eIF4A1 and eIF4E targets, these data establish that 
eIF4F negatively regulates translation via enforcement of miRNA-mediated repression in 
melanoma.
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Taken together, our data implicate features in the CDS and 3′UTR of target mRNAs as 
determinants of direct targets that are common to eIF4A1 and eIF4E, whereas distinct 
5′UTR features primarily determine eIF4A1- and eIF4E-specific targets. It is likely that the 
lack of predictive 5′UTR features among common targets reflects neutralization of the 
opposing 5′UTR features that determine factor-specific responses. These findings may be 
useful in predicting a priori which classes of proteins will be most affected by therapeutic 
inhibitors of eIF4A1 or eIF4E.
DISCUSSION
Significant efforts have been made to identify translational targets of eIF4F during 
transformation and cancer progression. Still, the rules governing eIF4F-dependent 
translation initiation and the key drivers of malignant phenotypes are not well understood. 
We demonstrate that although the eIF4F subunits eIF4A1 and eIF4E commonly promote 
melanoma proliferation and invasion, they have distinct effects on the melanoma proteome.
Proteomics defines eIF4F targets that contribute to melanoma phenotypes
Mass spectrometry is typically insensitive to small fold-changes, but recently developed 
MS3 overcomes this limitation (23) and enables reliable detection of physiological protein 
changes. We leveraged this technology to generate the first eIF4A1- and eIF4E-dependent 
proteomes. These datasets provide a new layer of insight into the phenotypic effects of 
eIF4A1 and eIF4E in cancer cells. A proteomic approach has distinct advantages over 
translation efficiency-based methods. The first is that for protein-coding genes, the proteins 
themselves, not mRNAs, are the primary effectors of biological processes and are thus much 
more closely related to cellular phenotypes. The second is that ribosome occupancy is only 
one of many factors contributing to cellular protein levels. Thus, changes in ribosome 
occupancy don’t always correspond with altered protein levels. The major limitation to 
proteomics is that it can be difficult to discern direct from indirect targets. We overcame this 
by performing an integrative mRNA analysis that enriched for direct translational targets. 
Still, integration of RNA expression, ribosome occupancy and proteomic data will be 
required to generate a complete model of eIF4F-dependent cancer formation and 
progression.
eIF4E and eIF4A1 have distinct effects on the proteome
Binding of eIF4E to the m7G cap (32) recruits eIF4G (33). eIF4G subsequently recruits 43S 
subunits and eIF4A (34), which melts local secondary structure to facilitate 43S scanning 
(35). These coordinated events are considered the critical steps in cap-dependent 
translational regulation. Because these three components are tightly associated, it is logical 
that knockdown of any of these factors could lead to common effects on protein translation.
Though a few eIF4A1- and eIF4E-specific targets have been identified (22), it was surprising 
that eIF4A1 and eIF4E proteomes were strongly discordant. Depletion of eIF4A1, in 
particular, had many effects that were not shared by eIF4E. While opposing regulation at the 
mRNA level may mask some eIF4E-dependent protein expression changes, it is likely that 
the different biochemical activities of eIF4E and eIF4A within the eIF4F complex or eIF4F-
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independent functions explain factor-specific dependencies. For example, eIF4A, not eIF4E, 
associates with mRNAs during the pioneer round of translation (36), which is required for 
mRNA quality control via nonsense-mediated decay.
Combinatorial models of eIF4F function on target mRNAs
Our data demonstrate that eIF4A1 and eIF4E target separate transcripts based on distinct 
sequence and structural features in the 5′UTR, but their shared targets are defined by 
common features in the CDS and 3′UTR. CDS and 3′UTR features may therefore predict 
translational responses to eIF4F independently of 5′UTR features. Consistent with our 
observations, a computational analysis of two published eIF4E overexpression datasets 
reported several features of the CDS and 3′UTR – including CDS GC content and 3′UTR 
length - that influence translational responses (17). Thus, CDS and 3′UTR associations may 
be more robust than 5′UTR features that tend to contribute inconsistently across studies.
The mechanism through which eIF4F is linked to non-5′UTR features has been elusive. Our 
data support a role for eIF4E and eIF4A in translation inhibition by promoting miNA-
mediated repression at the 3′UTR. Given the number of tumor suppressive miRNAs that 
have been discovered, including miR-211 in melanoma (37), this activity of the eIF4F 
complex may be critical for cancer progression. However, other predictive features also 
influenced eIF4F-dependent protein output on a genome-wide scale, and more research is 
necessary to understand the cooperative or antagonistic interactions among different features 
on a given transcript.
For example, the rare codon effect is the first evidence that potentially links eIF4F sensitivity 
to the efficiency of translation elongation. Initiation is often thought of as the rate-limiting 
step in translation, but elongation can be limiting in certain contexts (38) and ribosome 
profiling has begun to reveal novel mechanisms through which elongation regulates the 
proteome (39). This raises the possibility that eIF4F sensitivity depends, in part, on which 
step of translation (initiation or elongation) is limiting for a given transcript. An alternative 
explanation for the rare codon effect could be the role of codon usage in mRNA and protein 
stability, which is still poorly understood (40). Regardless, our data demonstrate that eIF4F 
sensitivity is a function of translational dynamics across the length of the transcript, not just 
in the 5′UTR. Thus, we propose that more accurate models of eIF4F dependence will 
integrate features of the 5′UTR, CDS and 3′UTR that together modulate protein output.
eIF4F inhibition is a promising approach to cancer therapy
eIF4F is frequently and homogeneously overexpressed in many cancers, and in virtually all 
cells of a tumor mass (41). Thus, eIF4F inhibition will target greater numbers of tumor cells 
than therapies that target subclonal genetic or gene expression changes. Moreover, cancer 
cells can become addicted to elevated levels of protein synthesis (42), potentially creating a 
therapeutic window to selectively target them.
Molecules that inhibit the eIF4E-cap interaction (43), eIF4E-eIF4G interaction (44) and 
eIF4A helicase activity (45,46) are effective in preclinical models. An antisense 
oligonucleotide inhibitor of eIF4E has shown particular promise (47,48) and is currently in 
Phase II clinical trials as part of combination therapies for prostate (NCT01234025) and 
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non-small cell lung (NCT01234038) cancers. Our data suggest that therapeutically targeting 
different eIF4F subunits in the same cancer will lead to disparate molecular outcomes that 
influence on- and off-target effects. Additionally, we observed a robust increase in 
expression of proteins required for oxidative phosphorylation in eIF4A1- and eIF4E-
depleted melanoma, whereas the opposite was found in eIF4E-depleted MCF7 human breast 
cancer cells (22,49). The data from both cell types are compelling, and the discrepancy 
likely reflects differences in baseline molecular or metabolic state of the different cell types. 
Thus, the effects of eIF4F inhibitors should not only be evaluated within cancer-subtypes, 
but among cancer subtypes with distinct molecular makeups. Ultimately, it is possible that 
rational selection of eIF4F inhibitors could lead to greater therapeutic effects and fewer off-
target effects than general inhibition of the upstream signaling pathways that converge on 
eIF4F.
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Figure 1. eIF4A1 and eIF4E are positive regulators of melanoma proliferation and invasion
Proliferation rates (left) and invasion rates (center) with representative images (right) for the 
(A) WM858 MSTC treated with siRNAs against eIF4A1 (si-eIF4A1 #1), eIF4E (si-eIF4E 
#1) or scrambled sequence (si-Scr), (B) WM46 MSTC treated with mammalian expression 
vectors encoding eIF4A1 (oe-eIF4A1), eIF4E (oe-eIF4E) or empty vector (oe-Empty) and 
(C) A375 melanoma cell line treated with si-Scr, or one of two independent siRNAs against 
eIF4A1 and eIF4E. Proliferation values were normalized to day one, and plotted relative to 
si-Scr. Percent invasion is calculated as the number of invasive cells on a matrigel-coated 
filter relative to the number of migratory cells on an uncoated control filter seeded at the 
same density. Error bars = standard error of the mean (SEM), n≥3 replicates/treatment, 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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Figure 2. eIF4A1 and eIF4E commonly regulate cell cycle and oxidative phosphorylation
(A) Heatmap, hierarchically clustered by sample and gene, showing log2 fold-change 
relative to si-Scr for differentially expressed proteins in A375 treated with si-eIF4A1 #1 or 
si-eIF4E #1 (log2 fold-change ≥|1.25|, FDR<0.1). (B) Overlap between decreased (blue) or 
increased (red) proteins with each siRNA treatment. (C) Enriched Reactome pathways 
among decreased or increased proteins in the si-eIF4A1 #1 or si-eIF4E #1 treatments. In 
cases where multiple enriched pathways were under the same parent pathway, only the 
parent pathway has been shown. For complete enrichment results, see Table S1. (D) 
Enrichment plots for the commonly regulated Reactome categories, Cell Cycle and 
Tricarboxylic Acid Cycle/Eelectron Transport Chain (TCA/ETC). Black lines indicate the 
rank positions of category members based on average fold-change in all knockdown 
treatments. NMD=nonsense mediated decay, EJC=exon junction complex.
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Figure 3. The eIF4F-dependent cell cycle network influences melanoma patient survival
(A) Commonly regulated proteins that are annotated to the Reactome Cell Cycle pathway 
mapped onto phases of the cell cycle based on their Reactome subcategory annotations. 
Proteins that mediate transitions or function in multiple phases are shown in the gaps. Blue 
font denotes decreased protein expression level. (B) The frequency of each cell cycle phase 
in A375 cells treated with si-Scr, si-eIF4A1 or si-eIF4E (error bars = SEM, n=3 replicates). 
(C) The frequency of cells expressing the apoptotic marker, annexin 5 (ANXA5), or dead 
cell marker, propidium iodide (PI), in A375 cells treated with si-Scr, si-eIF4A1 or si-eIF4E 
(error bars = SEM, n=3 replicates). (D) Kaplan-Meier survival curves generated from 328 
cutaneous melanoma patients in TCGA. Patients used to generate the eIF4E curve were in 
the first or fourth quartiles based on normalized expression of the indicated protein (n=82 
per group). Patients used to generate the CDK1/CCNB1/CCND1 curve had above-median 
and below-median expression of all three proteins. The less stringent cutoff was applied to 
obtain a roughly equivalent sample size. For (B–D), *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001.
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Figure 4. Integrated RNA and protein analysis defines direct translational targets of eIF4A1 and 
eIF4E
(A) Overlap in transcripts detected in A375 by RNA-seq (FPKM≥1, n=2 biological 
replicates per treatment) and MS3 (peptides≥1, n=3 biological replicates per treatment). (B) 
Average log2 protein versus average log2 mRNA fold-change for differentially expressed 
proteins in si-eIF4A1 #1 or si-eIF4E #1 treatments. Red and blue points denote proteins that 
do not have a concordant change in mRNA level (mRNA fold-change in 2 biological 
replicates ≤1.25 and/or FDR<0.1 for increased proteins, ≥ −1.25 and/or FDR<0.1 for 
decreased proteins). (C) Manually-clustered heatmap showing log2 fold-change at the 
mRNA and protein level for differentially expressed proteins that are annotated to the 
commonly enriched Cell Cycle or TCA/ETC Reactome pathways. ‘Factor-specific’ refers to 
proteins that are directly regulated by one factor and indirectly regulated by the other.
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Figure 5. CDS and 3′UTR features predict direct regulation by eIF4A1- and eIF4E
(A) Manually-clustered heatmap of effect sizes (Cliff’s D) for thirteen mRNA features 
among direct targets of eIF4A1, eIF4E, or both factors. Dotted lines demarcate 5′UTR, 
CDS, 3′UTR and whole transcript features. p-values are shown for features where p<0.05 
and effect size is greater than 20%. (B) Fold-repression of a miRNA-targeted Renilla 
luciferase reporter relative to a non-targeted firefly luciferase reporter. *p<0.05, **p<0.01.
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